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PCLINICAL RESEARCH Clinical Trial
Carotid Artery Revascularization
in High-Surgical-Risk Patients Using
the Carotid WALLSTENT and FilterWire EX/EZ
1-Year Outcomes in the BEACH Pivotal Group
Sriram S. Iyer, MD, FACC,* Christopher J. White, MD, FACC,† L. Nelson Hopkins, MD,‡
Barry T. Katzen, MD,§ Robert Safian, MD, FACC, Mark H. Wholey, MD,¶
William A. Gray, MD, FACC,# Rocco Ciocca, MD,** William B. Bachinsky, MD, FACC,††
Gary Ansel, MD,‡‡ James D. Joye, DO, FACC,§§ Mary E. Russell, MD, FACC,**
for the BEACH Investigators
New York and Buffalo, New York; New Orleans, Louisiana; Miami, Florida; Royal Oak, Michigan; Pittsburgh
and Harrisburg, Pennsylvania; Natick, Massachusetts; Columbus, Ohio; and Mountain View, California
Objectives The multicenter, single-arm BEACH (Boston Scientific EPI: A Carotid Stenting Trial for High-Risk Surgical Pa-
tients) evaluated outcomes in high-surgical-risk patients with carotid artery stenosis treated with the Carotid
WALLSTENT plus FilterWire EX/EZ Emboli Protection System (Boston Scientific, Natick, Massachusetts).
Background Carotid artery stent (CAS) placement offers a less invasive alternative for high-risk surgical carotid endarterec-
tomy (CEA) patients.
Methods The trial enrolled 480 pivotal patients who were candidates for carotid revascularization but considered high surgical
risk due to pre-specified anatomic criteria and/or medical comorbidities. The primary end point (all stroke, death, or
Q-wave myocardial infarction [MI] through 30 days; non–Q-wave MI through 24 h; and ipsilateral stroke or neurologic
death through 1 year) was compared with a proportionally weighted objective performance criterion (OPC) of 12.6%
for published surgical endarterectomy results in similar patients, plus a pre-specified noninferiority margin of 4%.
Results Among pivotal patients, 41.2% were at high surgical risk due to comorbid risk factors, and 58.8% due to ana-
tomic risk factors; 76.7% were asymptomatic with flow-limiting carotid stenosis 80%. At 1 year, the composite
primary end point occurred in 8.9% (40 of 447), with a repeat revascularization rate of 4.7%. With an upper
95% confidence limit of 11.5% for the primary composite end point, the BEACH trial results met the pre-
specified criteria for noninferiority relative to the calculated OPC plus noninferiority margin (16.6%) for historical
surgical CEA outcomes in similar patients (p  0.0001 for noninferiority).
Conclusions The BEACH trial results demonstrate that CAS with the WALLSTENT plus FilterWire embolic protection is non-
inferior (equivalent or better than) to CEA at 1-year in high-surgical-risk patients (Boston Scientific Embolic Pro-
tection, Inc. [EPI]: A Carotid Stenting Trial for High-Risk Surgical Patients [BEACH]; http://clinicaltrials.gov/ct2/
show/NCT00316108?termNCT00316108&rank1; NCT00316108). (J Am Coll Cardiol 2008;51:427–34)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.045t
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Aarotid artery disease is a major cause of ischemic stroke,
ith an absolute risk directly related to the severity of
tenosis and presence of neurologic symptoms (1,2). Surgi-
al removal of atherosclerotic plaque (carotid endarterec-
rom the *Lenox Hill Hospital, New York, New York; †Ochsner Clinic Foundation,
ew Orleans, Louisiana; ‡University of Buffalo, Buffalo, New York; §Baptist
ospital, Miami, Florida; William Beaumont Hospital, Royal Oak, Michigan;
Pittsburgh Vascular Institute, Pittsburgh, Pennsylvania; #Columbia University
edical Center, New York, New York; **Boston Scientific Corporation, Natick,
assachusetts; ††Pinnacle Health at Harrisburg Hospital, Harrisburg, Pennsylvania; aomy [CEA]) can successfully reduce the incidence of
erebral infarction in both symptomatic patients and asymp-
omatic patients with carotid stenosis 60% (3–7). Some
‡Riverside Methodist Hospital, Columbus, Ohio; and §§El Camino Hospital,
ountain View, California. The BEACH trial was supported by Boston Scientific
orporation. The current affiliation for Dr. Ciocca is University of Massachusetts
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scent Translational Sciences, Carlisle, Massachusetts.
Manuscript received July 23, 2007; revised manuscript received September 4, 2007,
ccepted September 17, 2007.
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The BEACH Trial 1-Year Outcomes January 29, 2008:427–34patients, however, are unable to
safely undergo CEA due to un-
favorable anatomy or comorbid
conditions (8–11), and are in-
creasingly considered for treat-
ment by carotid artery stent
(CAS) placement with cerebral
embolic protection (12–19). The
BEACH (Boston Scientific EPI:
A Carotid Stenting Trial for
High-Risk Surgical Patients)
trial is an ongoing, prospective,
multicenter, single-arm trial
evaluating the outcomes of high-
surgical-risk patients treated
with the Carotid WALL-
STENT and either the Filter-
Wire EX or FilterWire EZ Em-
boli Protection System distal
filter device (Boston Scientific
Corp., Natick, Massachusetts).
Thirty-day outcomes for the piv-
tal group were reported previously (20); this report dis-
usses 1-year pivotal outcomes.
ethods
tudy design. The BEACH trial was designed to test if
utcomes in high-surgical-risk patients treated with the
ALLSTENT plus FilterWire EX/EZ would be non-
nferior to a calculated objective performance criterion
OPC) agreed upon with the U.S. Food and Drug Admin-
stration (FDA). The primary end point was 1-year com-
osite morbidity and mortality. Noninferiority was assessed
y comparing the upper 95% confidence interval (CI) of the
bserved end point to a literature-derived OPC for CEA in
atients with similar demographics, with a pre-specified
oninferiority margin (delta) of 4%.
Patients were enrolled into a roll-in phase to familiarize
hysicians with the protocol and devices (first 1 to 9 patients
er site), a pivotal phase, or a bilateral registry (patients
equiring treatment for both carotid arteries). After review
f roll-in periprocedural outcomes, investigators were al-
owed to proceed to the pivotal phase. This report discusses
-year outcomes, but study patients continue to be moni-
ored through 3 years of follow-up.
atient selection, device, procedure, and follow-up. Details
f patient selection, device, procedure, and follow-up have
een described (20). Briefly, eligible patients with carotid
isease met general inclusion criteria plus at least 1 defini-
ion of surgical high risk based on specific anatomic and
omorbid clinical criteria (Table 1). The common carotid
rtery (CCA), bifurcation, or internal carotid artery (ICA)
as 4 to 9 mm in diameter, with 50% stenosis by
ngiography in symptomatic patients and 80% in asymp-
Abbreviations And
Acronyms
CAS  carotid artery
stent/stenting
CCA  common carotid
artery
CEA  carotid
endarterectomy
CI  confidence interval
FDA  Food and Drug
Administration
ICA  internal carotid
artery
MI  myocardial infarction
NIHSS  National
Institutes of Health
Stroke Scale
OPC  objective
performance criterion
PSV  peak systolic
velocityomatic patients as determined by the operator (visual Estimate) per NASCET (North American Symptomatic
arotid Endarterectomy Trial) criteria (7). The protocol
as approved by institutional review boards of the 47
articipating U.S. institutions; written informed consent
as obtained from patients before enrollment, and the trial
omplied with the Declaration of Helsinki. Trial results are
eported on the National Institutes of Health website.
Election of stent size (Carotid WALLSTENT Monorail
ajor Eligibility Criteria
Table 1 Major Eligibility Criteria
Inclusion criteria
General criteria
Age 18 yrs
Unilateral or bilateral atherosclerotic or restenotic lesions in native CCA, ICA,
or carotid bifurcation
Symptoms plus stenosis 50% of the luminal diameter by angiography
No symptoms plus stenosis 80% of the luminal diameter by angiography
Target segment reference diameter 4.0 and 9.0 mm
Vessel diameter distal to target lesion 3.5 and 5.5 mm as an optimal
“landing zone” for the FilterWire
Life expectancy 1 yr post-index procedure
Criteria for high-risk
Anatomic high-risk category (1 criterion required)
Restenosis post-carotid endarterectomy
Contralateral total occlusion with a qualifying lesion on the ipsilateral side
Previous neck or head radiation therapy/surgery including area of stenosis
Surgically inaccessible lesions at or above C2 or below clavicle
Spinal immobility of neck
Tracheostoma
Laryngeal palsy or laryngectomy
Comorbid high-risk category 1 (1 criterion required)
Unstable angina (CCS class III/IV)
Left ventricular ejection fraction 30%
Congestive heart failure (NYHA functional class III/IV)
Planned coronary artery bypass graft or valve replacement post-carotid
index procedure
Chronic obstructive pulmonary disease manifested with forced expired
volume 30%
Comorbid high-risk category 2 (2 criteria required)
Age 75 yrs
Major diseased coronary arteries (2) with 70% stenosis (patients with
angina)
Planned peripheral vascular surgery, or other major surgeries post-carotid
stenting
Myocardial infarction 72 h and 30 days
Exclusion criteria
Patient experienced evolving, acute, or recent stroke within 21 days of study
evaluation
Patient experienced a major stroke (NIHSS score 15)
Known cardiac sources of emboli likely to be associated with cerebral
ischemic events
Myocardial infarction 72 h before the index procedure
Any surgery requiring general anesthesia 30 days preceding stent procedure
Total occlusion of ipsilateral carotid artery
Pre-existing stent in ipsilateral carotid artery or in a contralateral vessel
30 days before procedure
Severe tandem lesions that cannot be covered with 1 stent
CA  common carotid artery; CCS  Canadian Cardiovascular Society; ICA  internal carotid
rtery; NIHSS  National Institutes of Health Stroke Scale; NYHA  New York Heart Association.ndoprosthesis, Boston Scientific Corp.) and emboli pro-
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January 29, 2008:427–34 The BEACH Trial 1-Year Outcomesection length and placement (FilterWire EX or FilterWire
Z Embolic Protection System, Boston Scientific Corp.)
ere based on the operator’s visual estimate of vessel
iameter. At the end of the procedure, the filter together
ith any contained material was collapsed and retrieved. All
atients were examined before (within 7 days) and after the
rocedure (per protocol, within 24 h and at the time of any
hange in clinical symptoms) by an independent neurologist
r neurosurgeon certified in the administration of the
ational Institutes of Health Stroke Scale (NIHSS). Pa-
ients were also monitored continuously during the proce-
ure and frequently during the in-hospital recovery period
y physician and nursing staff, including neurologic exam-
nations. All patients underwent carotid duplex ultrasonog-
aphy before the procedure and before discharge. Investiga-
or training included review of animal studies, on-site
roctoring to achieve competence in device implantation,
nd general training on the protocol. Independent ultra-
ound and angiographic core laboratories provided review of
ll studies throughout the course of the trial and validation
f site-determined entry criteria. Follow-up included ca-
otid duplex ultrasonography as well as independent neuro-
ogic examination using the NIHSS at 1, 6, and 12 months
nd yearly thereafter through 3 years.
rimary end point. The primary composite end point
ncluded all stroke, death, and Q-wave myocardial infarc-
ion (MI) through 30 days; non–Q-wave MI through 24 h;
nd ipsilateral stroke and neurologic death through 1 year.
dverse events were adjudicated by an independent clinical
vents committee. Analyses of all measurements obtained
ere performed according to published criteria by core
aboratories (Online Appendix 1) (20).
tatistical analyses. Harvard Clinical Research Institute
Online Appendix 1) performed data management and statis-
ical analyses with SAS version 8.2 or above (SAS Institute
ivotal Group Patientualificati n by H gh-Risk Criteria
Table 2 Pivotal Group PatientQualification by High-Risk Criteria
Condition* Percent (n)
Anatomic high-risk conditions
Restenosis post-carotid endarterectomy 34.2% (164)
Contralateral total occlusion with a qualifying lesion
on the ipsilateral side
18.1% (87)
Previous neck or head radiation therapy or surgery
that included the area of stenosis/repair or
ipsilateral radical neck dissection for cancer
10.8% (52)
Comorbid conditions (1 criterion qualifies)
Unstable angina (CCS class III/IV) 12.5% (60)
Known severe LVEF (30%) 12.1% (58)
Congestive heart failure (NYHA functional class III/IV) 11.7% (56)
Comorbid conditions (2 criteria qualifies)
Age 75 yrs 39.0% (187)
Two or more major diseased coronary arteries with
70% stenosis at the time of index procedure in
patients with a history of angina
21.7% (104)10% of patients; n  480.
LVEF  left ventricular ejection fraction; other abbreviations as in Table 1.nc., Cary, North Carolina). Freedom from 1-year morbidity
nd mortality was determined by Kaplan-Meier analysis; pre-
ictors were identified using single- and multi-variable logistic
egression analyses (p  0.05 for significance).
In the BEACH trial, CAS was compared to CEA
control) to determine if stenting was non-inferior to
urgery in the high-surgical-risk patient population. The
EA comparator was a calculated OPC applied to the
rimary composite end point. The mathematical equation
in the following text) representing the OPC was derived
sing data in the literature (Online Appendix 2) from CEA
utcomes in high-surgical-risk patients and reflects the
Figure 1 Carotid Artery Stenosis
Before and After Stent Implantation
Mean percent diameter stenosis in the pivotal population decreased from
71.6% before the index procedure to 10.8% after the procedure. Labels on the
x-axis from left to right represent stenosis in 10% intervals (e.g., 90% to 100%
stenosis, 80% to 90%, and so on).
atient and Lesion Baseline Characteristics
Table 3 Patient and Lesion Baseline Characteristics
Characteristic Value (n)*
Patient
Age, in yrs† 70.9  9.3 (480)
Male gender (%) 65.2 (313)
History of cerebrovascular accident (%) 28.1 (135)
History of transient ischemic attack (%) 30.4 (146)
Previous carotid endarterectomy (%) 40.6 (195)
History of congestive heart failure (%) 21.7 (103)
Prior myocardial infarction (%) 35.4 (170)
History of hypertension (%) 89.4 (429)
Current/prior smoking (%) 74.6 (358)
Lesion
ICA (% patients) 88.3% (424)
CCA (% patients)‡ 11.7% (56)
Lesion length (mm)† 15.1  7.2 (480)
De novo (%) 66.0% (317)
Diameter stenosis (%)† 71.6  10.7 (479)
ICA/CCA ratio† 5.3  3.1 (420)
n 480; †mean standard deviation; ‡bifurcation lesions for this analysis were included under
he CCA category.
Abbreviations as in Table 1.
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The BEACH Trial 1-Year Outcomes January 29, 2008:427–34alculated surgical risk associated with anatomical condi-
ions (OPC - Anatomical) plus that associated with comorbid
onditions (OPC - Comorbid). The weighted OPC (OPC -
eighted), reflecting the calculated CEA risk for the
EACH primary end point, was obtained by multiplying
he anatomical and comorbid risk by the percentage of
EACH patients in the surgical high risk anatomical (A)
nd surgical high risk comorbid (C) groups, respectively, as
hown in the equation below.
With the concurrence of the U.S. FDA, 11% was selected
s OPC - Anatomical and 15% as OPC - Comorbid, with the
igher risk assumed in cases qualifying for both. Using the
nrollment percentages in each category (58.8% anatomical
rimary End Point—Pivotal Group
Table 4 Primary End Point—Pivotal Group
Event Rate (%)* 95% CI
One-year morbidity and mortality† 8.9% (40) 11.5%‡
Non–Q-wave MI (through 24 h) 0.9% (4) (0.2%–2.3%)
Death, stroke, Q-wave MI
(through 30 days)
5.4% (24) (3.5%–7.9%)
Death 1.6% (7) (0.6%–3.2%)
Stroke 4.5% (20) (2.8%–6.8%)
Ipsilateral 3.4% (15) (1.9%–5.5%)
Major ischemic 1.1% (5) (0.4%–2.6%)
Minor ischemic 2.0% (9) (0.9%–3.8%)
Hemorrhagic 0.2% (1) (0.0%–1.2%)
Contralateral 1.1% (5) (0.4%–2.6%)
Major ischemic 0.0% (0) (0.0%–0.8%)
Minor ischemic 0.7% (3) (0.1%–2.0%)
Hemorrhagic 0.4% (2) (0.1%–1.6%)
Q-wave MI 0.2% (1) (0.0%–1.2%)
Neurologic death, ipsilateral stroke
(31 to 360 days)
3.1% (14) (1.7%–5.2%)
Neurologic death 1.6% (7) (0.6%–3.2%)
Ipsilateral stroke 2.5% (11) (1.2%–4.4%)
n  447 at 1 year; †based on adjudicated events in evaluable patients through 360 days;
1-sided upper confidence interval (CI). Numbers are % (n).
MI  myocardial infarction.
dverse Event Rates in the BEACH Pivotal Group Symptomatic and
Table 5 Adverse Event Rates in the BEACH Pivotal Group Sym
Symptoma
Event Rate (%)*
1-yr morbidity and mortality‡ 12.5% (13)
Non–Q-wave MI (through 24 h) 1.9% (2)
Death, stroke, Q-wave MI (through 30 days) 7.7% (8)
Death 1.0% (1)
Stroke 7.7% (8)
Major ischemic 1.9% (2)
Minor ischemic 3.8% (4)
Hemorrhagic 0.0% (0)
Q-wave MI 0.0% (0)
Neurologic death, ipsilateral stroke (31 to 360 days) 3.8% (4)
Neurologic death 1.9% (2)
Ipsilateral stroke 3.8% (4)
23.3% of the pivotal group population was symptomatic; †at 1 year, n 104 symptomatic patien
ays. Numbers are % (n).
Abbreviations as in Table 4.A] and 41.2% comorbid [C]), the calculated weighted
PC for this trial was 12.6%. Because true equivalency
annot be realized with less than an infinite sample size, an
DA-concurred pre-specified spread of 4% for the “delta”
efinition of equivalency was added to the weighted OPC to
ield an upper noninferiority boundary of 16.6%. The
EACH primary composite end point with a 1-sided upper
5% CI was compared with this boundary (weighted OPC
lus delta) to assess noninferiority of CAS to CEA. Statis-
ical significance was determined using a normal approxi-
ation test for a single proportion (Z test).
esults
he BEACH trial enrollment began February 2002 and
nded December 2003 with 189 roll-in phase patients, 78
atients in the bilateral registry, and 480 patients in the
ivotal study group. The trial was temporarily suspended on
ecember 24, 2002 due to carotid WALLSTENT mal-
unctions and re-initiated on June 11, 2003 after the cause
f the malfunctions was identified and corrected. Of 47
enters participating (Online Appendix 3), 36 contributed
o the pivotal group. Data for patients receiving the Filter-
ire EX and FilterWire EZ were pooled because there was
o statistically significant difference in end points between
hese groups after adjustment for baseline percent diameter
tenosis.
aseline and procedural characteristics—pivotal group.
mong pivotal patients, 41.2% had comorbid risk factors, and
8.8% had anatomical risk factors, resulting in a calculated
oninferiority margin (OPC plus 4% delta) of 16.6% for the
-year composite primary end point. Table 2 lists patient
ualifications by individual high-risk criteria; Table 3 lists
aseline patient and lesion characteristics. Over three-
uarters of the patients (77%, 368 of 480) were asymptom-
tic; 99.2% of whom had site-reported (visual estimate)
arotid stenosis between 80.0% and 99.9%. Quantitative
mptomatic Patients
atic and Asymptomatic Patients
tients (n  112)* Asymptomatic Patients (n  368)
95% CI Rate (%)† 95% CI
(6.8%–20.4%) 7.8% (27) (5.2%–11.2%)
(0.2%–6.8%) 0.6% (2) (0.1%–2.1%)
(3.4%–14.6%) 4.7% (16) (2.7%–7.4%)
(0.0%–5.2%) 1.7% (6) (0.6%–3.8%)
(3.4%–14.6%) 3.5% (12) (1.8%–6.0%)
(0.2%–6.8%) 0.9% (3) (0.2%–2.5%)
(1.1%–9.6%) 1.5% (5) (0.5%–3.4%)
(0.0%–3.5%) 0.3% (1) (0.0%–1.6%)
(0.0%–3.5%) 0.3% (1) (0.0%–1.6%)
(1.1%–9.6%) 2.9% (10) (1.4%–5.3%)
(0.2%–6.8%) 1.5% (5) (0.5%–3.4%)
(1.1%–9.6%) 2.0% (7) (0.8%–4.1%)
n 344 asymptomatic patients; ‡based on adjudicated events in evaluable patients through 360Asy
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January 29, 2008:427–34 The BEACH Trial 1-Year Outcomesnalysis of percent diameter stenosis determined by the core
ab for the entire pivotal group was 71.6  10.7% (mean 
tandard deviation); this decreased to 10.6  14.4% post-
rocedure (Fig. 1) with 99.8% of patients having 50%
ost-procedure stenosis. Procedure success—a composite
nd point based on patients in whom a system placement
ttempt was made and including system technical success
successful delivery, deployment, and retrieval of the de-
ices; 98.3%); angiographic success (in-stent residual diam-
ter stenosis30% post-procedure; 90.8%); and the absence
f death, stroke, or MI within 24 h of the index procedure—
as 87.6% (418 of 477).
linical outcomes—pivotal group. At 30 days the com-
osite major adverse event rate of death, stroke, and Q-wave
I in the pivotal group was 5.4% (24 of 447) (Table 4). The
-year primary composite end point was 8.9% (40 of 447
atients) (Table 4). The 1-sided 95% upper CI was 2.6%,
esulting in an upper limit (central estimate plus 95% CI) of
1.5% for the BEACH primary end point. This value was
elow the control comparator of 16.6% (calculated OPC for
imilar CEA patients of 12.6% plus the pre-specified delta
f 4%), thereby indicating noninferiority of CAS to CEA (p
0.0001 for noninferiority).
Table 5 shows primary end point outcomes for asymp-
omatic and symptomatic patients. There were no signifi-
ant differences in rates between the 2 groups though there
as a weak trend towards a higher rate of the primary end
oint for symptomatic versus asymptomatic patients at 1
ear (12.5% vs. 7.8%, respectively, p  0.14). Patients
ualifying for the trial with comorbid high-surgical-risk
actors had a significantly higher 30-day event rate than did
hose with anatomical high-risk factors (14.3% vs. 5.3%,
espectively, p  0.002). Advanced age (75 years) was
ssociated with significantly worse outcomes, including late
eurologic death (Fig. 2).
Freedom from morbidity and mortality was 91.6% at 1
ear with most events occurring at 30 days (Fig. 3).
utcomes from 31 to 360 days (Table 6) include a late
eurologic event rate related to stenting of 2.7% (12 of 447).Figure 2 Significant Effects of Age on Outcomes *
ihe 1-year restenosis rate, defined as 70% stenosis by
uplex ultrasound, was 8.9% (40 of 447), with a 1-year
epeat target vessel revascularization rate of 4.7% (20 of 425)
ncluding 17 asymptomatic patients with repeat revascular-
zation driven by duplex findings alone. Per the BEACH
rial protocol, a carotid angiogram was required if the duplex
ltrasound demonstrated a restenosis of70%. This poten-
ially increased the re-intervention rate above what would be
xpected for this primarily asymptomatic group.
redictors of 1-year morbidity and mortality—pivotal
roup. By univariate analysis, age 75 years (p  0.0004)
nd the comorbid risk category (p  0.0017) were signifi-
ant predictors of 1-year morbidity and mortality. Multi-
ariate analysis identified these same significant predictors
p  0.0002 and p  0.0092, respectively) plus diabetes (p
0.0357) and symptomatic status (p  0.0774).
urability of revascularization—ultrasound results in
he pivotal group. The ICA/CCA peak systolic velocity
PSV) ratio (mean  standard deviation) before the proce-
ure was 5.3  3.1. This improved to 1.4  0.5 immedi-
tely after the procedure and remained improved at 6
onths (1.9  1.2) and 1 year (1.9  1.1). Additionally,
here was no progression of ICA PSVmaximum over the latter
months of follow-up (Table 7).
iscussion
his prospective, multicenter, single-arm trial compared the
utcomes of carotid stenting with a distal emboli protection
lter to a calculated OPC based on the historical rate of
Figure 3 Freedom From Morbidity and
Mortality (Kaplan-Meier Analysis)
ate Neurologic Events
Table 6 Late Neurologic Events
Event (31 Through 360 days) Number
Neurologic death and/or ipsilateral stroke 14
Neurologic death plus ipsilateral stroke* 5†
Neurologic death not related to ipsilateral stroke* 2
Ipsilateral stroke without death‡ 7†7 neurologic deaths occurred between 34 and 197 days post-intervention; †related to stenting; ‡7
psilateral strokes without neurologic death occurred between 40 and 346 days.
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The BEACH Trial 1-Year Outcomes January 29, 2008:427–34imilar end points in high-surgical-risk patients undergoing
EA. The observed composite 1-year morbidity and mor-
ality rate was 8.9%, with a 95% 1-sided upper confidence
imit extending to 11.5%. This was significantly (p 
.0001) below the 16.6% noninferiority boundary defined as
he 12.6% historical rate in comparable surgical patients plus
he pre-specified noninferiority margin of 4%. Therefore,
he BEACH trial demonstrates that this form of CAS with
istal embolic protection using the WALLSTENT in
ombination with the FilterWire emboli protection system
s noninferior to (equivalent or better than) surgical CEA in
igh-surgical-risk patients (18,19).
Moreover, most of the morbidity and mortality in the
-year primary end point was due to early events. The rate
or death, stroke, and Q-wave MI was 5.4% (CI 3.5% to
.9%) through 30 days; most events (3.4% [CI 2.8% to
.8%]) were ipsilateral stroke (major [1.1%], minor [2.0%],
emorrhagic [0.2%]) (20). This is similar to the 4.8% rate of
eath, stroke, or MI in the randomized SAPPHIRE (Stent-
ng and Angioplasty with Protection in Patients at High-
isk for Endarterectomy) trial, which included 29.9%
ymptomatic patients in the stenting arm (18). The rate for
ymptomatic BEACH patients (7.7%) is similar to the
0-day event rate in 2 recent prospective randomized
linical trials of symptomatic carotid occlusive disease pa-
ients that failed to show a benefit of stenting over surgery
21,22). In the SPACE (Stent-Supported Percutaneous
ngioplasty of the Carotid Artery versus Endarterectomy)
rial, the 30-day 6.8% rate of death or ipsilateral ischemic
troke in the stenting arm was not statistically different from
he 6.3% rate in the CEA arm, and failure to demonstrate
oninferiority of CAS to CEA despite similar event rates
eflects premature termination of enrollment at 1,183 pa-
ients, resulting in inadequate statistical power (21). The
VA-3S (Endarterectomy versus Angioplasty in Patients
ith Symptomatic Severe Carotid Stenosis) trial reported a
.6% incidence of any stroke or death in the stenting arm at
0 days with a corresponding CEA rate of 3.9%, possibly
eflecting relative inexperience of CAS operators compared
ith very experienced surgical operators, as well as prema-
ure termination of the trial for safety concerns (22). In
ddition, comparison between U.S. and European studies
ay be limited as there is no distinction between patients
onsidered high-risk or non–high-risk for surgery outside
he U.S. The results of these 2 symptomatic trials, thus, are
nternal Carotid Artery Maximum Peak Systolic Velocity
Table 7 Internal Carotid Artery Maximum Peak Systolic Velocit
Pivotal Group Pre-Procedure Post-
ICA PSVmax 346.1  148.0, 436,
332.2–360.0
115.8 
112Values are mean  standard deviation (cm/s), n, 95% confidence interval.
ICA  internal carotid artery; PSVmax  maximum peak systolic velocity.utliers from the lower CAS rates seen in most of the
igh-surgical-risk carotid stenting trials.
In the BEACH trial, carotid duplex ultrasound at 6
onths and 1 year indicated continued vessel patency, as
eflected in a 1-year restenosis rate of 8.9%, a target vessel
evascularization rate of 4.7%, and a stent-associated late
eurologic event rate of 2.7%. The overall 8.6% composite
-year end point in the BEACH trial also compares
avorably to earlier trials. In the SAPPHIRE trial, the
rimary end point (death, stroke, or MI at 30 days plus
psilateral stroke or death from neurologic causes within 31
ays to 1 year) was 12.2% (18). In the high-risk stent
egistry ARCHeR (Acculink for Revascularization of Ca-
otids in High Risk Patients) (23.8% symptomatic patients),
he primary end point (death, stroke, MI at 30 days plus
psilateral stroke at 1 year) was 9.6% (19). In this high-risk
atient population, confounding coronary and pulmonary
orbidities are common, but their influence is limited by
he use of a 1-year end point restricted to neurologic death
nd ipsilateral stroke beyond 30 days. The concordance in
ure neurologic outcomes for the BEACH trial and 1-year
esults reported in 2 other large studies involving carotid
tenting and high-surgical-risk patients with similar end
oints indicates that CAS can be reproducibly achieved in
his patient population.
Older age was identified as a significant predictor of poor
utcome as patients 75 years or older experienced higher
vent rates. Increased procedural risk may be attributable, in
art, to a number of factors commonly associated with
dvanced age including excessive vessel tortuosity, arch
longation, and heavy calcification, which also contribute to
ncreased risk with stent placement (23). Plaque burden is
resumed to increase with age, leading to more events in the
lderly population independent of intervention (24). In the
ead-in phase of the CREST (Carotid Revascularization
ndarterectomy vs. Stent Trial) (30.7% symptomatic), oc-
ogenarians exhibited increased complications at 30 days
ith CAS (25). Higher risk has been seen in elderly patients
or both stenting and surgery, although improved devices
nd experience in CAS along with better patient selection
ave led to reductions in perioperative morbidity (26–33).
dvances notwithstanding, the observed CAS results in
lder patients highlight the need to use CAS with distal
mboli protection predominantly in patients at low risk for
tenting, unless their risks for CAS are elevated to an even
reater degree. Trials that enroll a high proportion of high
Time Point*
ure 6 Months 1 Year
, 452,
.6
146.9  73.5, 406,
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January 29, 2008:427–34 The BEACH Trial 1-Year Outcomestent risk patients would similarly be expected to show
igher complication rates, and operators should remember
hat medical management, in fact, may be a better choice for
atients deemed high risk for both CAS and CEA (34).
It is critical to recognize that there has been a tremendous
mount of progress made since the BEACH trial was
nitiated in 2002 regarding patient selection as a determi-
ant of CAS outcomes. While the BEACH trial was
esigned to evaluate patients considered high risk for
ndarterectomy, it did not exclude those patients who would
e considered high risk for stenting; the BEACH trial met
he primary end point with a major adverse event rate below
he FDA-agreed OPC. In asymptomatic patients with
evere carotid stenosis, the 30-day event rate was 4.7%,
hich compares favorably with the asymptomatic SAP-
HIRE group (5.4%) (18). However, recently drafted
ultispecialty consensus statements have concluded that
ith improved understanding of appropriate patient selec-
ion, the acceptable 30-day event rates for carotid stenting
hould be 3% for asymptomatic patients and 6% for
ymptomatic patients (35). The adoption of CAS as a
inimally invasive alternative to CEA will be dependent
pon both proper patient selection and appropriate physi-
ian training and experience. Further clinical trials should,
hus, evaluate patients who are considered low or normal
isk for both CEA and CAS—the majority of patients with
arotid artery occlusive disease. Only positive results from
his type of trial will move CAS from a niche procedure to
 mainstream treatment option or the dominant standard of
are.
onclusions
he 1-year primary end point of 8.9% (upper confidence
imit of 11.5%) for carotid stenting and emboli protection in
igh-surgical-risk patients treated in the BEACH trial
eets the criteria for noninferiority to the 16.6% severity-
djusted surgical OPC plus delta. In high-surgical-risk
atients who meet indications for carotid revascularization,
AS with emboli protection is not inferior to CEA at 1
ear.
cknowledgments
he authors thank Alex Shih, BS, Lynne Kelley, MD, and
uth Starzyk, PhD (Boston Scientific Corp.), for their
ssistance in the statistical analyses (A.S.) and in drafting
his manuscript (L.K. and R.S.).
eprint requests and correspondence: Dr. Sriram Iyer, Lenox
ill Hospital, 130 East 77th Street, Black Hall, 9th Floor, New
ork, New York 10021. E-mail: SRIUAB@aol.com.
EFERENCES
1. Barnett HJM, Taylor DW, Eliasziw M, et al. Causes and severity of
ischemic stroke in patients with internal carotid artery stenosis. JAMA
2000;283:1429–36.2. Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in
patients with asymptomatic internal-carotid-artery stenosis: North
American symptomatic carotid endarterectomy trial collaborators.
N Engl J Med 2000;342:1693–700.
3. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and
fatal strokes by successful carotid endarterectomy in patients without
recent neurological symptoms: randomized controlled trial. Lancet
2004;363:1491–502.
4. Barnett HJM, Taylor W, Eliasziw M, et al. Benefit of carotid
endarterectomy in patients with symptomatic moderate or severe
stenosis. N Engl J Med 1998;339:1415–25.
5. European Carotid Surgery Trialists’ Collaborative Group. Random-
ized trial of endarterectomy for recently symptomatic carotid stenosis:
final results of the MRC European carotid surgery trial. Lancet
1998;351:1379–87.
6. Executive Committee for the Asymptomatic Carotid Atherosclerosis
Study. Endarterectomy for asymptomatic carotid artery disease.
JAMA 1995;273:1421–8.
7. North American Symptomatic Carotid Endarterectomy Trial Collab-
orators. Beneficial effect of carotid endarterectomy in symptomatic
patients with high-grade stenosis. N Engl J Med 1991;325:445–53.
8. Bond R, Rerkasem K, Rothwell PM. Systematic review of the risks of
carotid endarterectomy in relation to the clinical indication for and
timing of surgery. Stroke 2003;34:2290–303.
9. Ouriel K, Hertzer NR, Beven E, et al. Preprocedural risk stratification:
Identifying an appropriate population for carotid stenting. J Vasc Surg
2001;33:728–32.
0. Shawl F, Kadro W, Domanski M, et al. Safety and efficacy of elective
carotid artery stenting in high-risk patients. J Am Coll Cardiol
2000;35:1721–8.
1. Wennberg D, Lucas F, Birkmeyer J, Bredenberg C, Fisher E.
Variation in carotid endarterectomy mortality in the Medicare popu-
lation. JAMA 1998;279:1278–81.
2. Safian RD, Bresnahan JF, Jaff MR, et al., for the CREATE Pivotal
Trial Investigators. Protected carotid stenting in high-risk patients
with severe carotid artery stenosis. J Am Coll Cardiol 2006;47:
2384–91.
3. Goodney PP, Schermerhorn ML, Powell RJ. Current status of carotid
artery stenting. J Vasc Surg 2006;43:406–11.
4. Burton KR, Lindsay TF. Assessment of short-term outcomes for
protected carotid angioplasty with stents using recent evidence. J Vasc
Surg 2005;42:1094–100.
5. Gray WA. Endovascular treatment of extra-cranial carotid artery
bifurcation disease. Minerva Cardioangiol 2005;53:69–77.
6. Alhaddad IA. Carotid artery surgery vs. stent: a cardiovascular per-
spective. Catheter Cardiovasc Interv 2004;63:377–84.
7. Wholey MH, Wholey MH. History and current status of endovascular
management for the extracranial carotid and supra-aortic vessels. J
Endovasc Ther 2004;11 Suppl II:II43–61.
8. Yadav JS, Wholey MH, Kuntz RE, et al., for the SAPPHIRE
Investigators. Protected carotid-artery stenting versus endarterectomy
in high-risk patients. N Engl J Med 2004;351:1493–501.
9. Gray WA, Hopkins LN, Yadav S, et al., for the ARCHeR Trial
Collaborators. Protected carotid stenting in high-surgical-risk pa-
tients: the ARCHeR results. J Vasc Surg 2006;44:258–69.
0. White CJ, Iyer SS, Hopkins LN, Katzen BT, Russell ME, for the
BEACH Trial Investigators. Carotid stenting with distal protection in
high surgical risk patients: the BEACH trial 30 day results. Catheter
Cardiovasc Interv 2006;67:503–12.
1. The Space Collaborative Group. 30 day results from the SPACE trial
of stent-protected angioplasty versus carotid endarterectomy in symp-
tomatic patients: a randomized non-inferiority trial. Lancet 2006;368:
1239–47.
2. Mas J-L, Chatellier G, Beyssen B, et al., for the EVA-3S Investiga-
tors. Endarterectomy versus stenting in patients with symptomatic
severe carotid stenosis. N Engl J Med 2006;355:1660–71.
3. Roubin GS, Iyer S, Halkin A, Vitek J, Brennan C. Realizing the
potential of carotid artery stenting: proposed paradigms for patient
selection and procedural technique. Circulation 2006;113:2021–30.
4. Störk S, van den Beld AW, von Schacky C, et al. Carotid artery
plaque burden, stiffness, and mortality risk in elderly men: a
prospective, population-based cohort study. Circulation 2004;110:
344 – 8.
22
2
2
2
3
3
3
3
3
3
F
O
p
434 Iyer et al. JACC Vol. 51, No. 4, 2008
The BEACH Trial 1-Year Outcomes January 29, 2008:427–345. Hobson RW II, Howard VJ, Roubin GS, et al., for the CREST
Investigators. Carotid artery stenting is associated with increased
complications in octogenarians: 30-day stroke and death rates in the
CREST lead-in phase. J Vasc Surg 2004;40:1106–11.
6. Setacci C, de Donato G, Chisci E, et al. Is carotid artery stenting in
octogenarians really dangerous? J Endovasc Ther 2006;13:302–9.
7. Stanzialie SF, Marone LK, Boules TN, et al. Carotid artery stenting in
octogenarians is associated with increased adverse outcomes. J Vasc
Surg 2006;43:297–304.
8. Villalobos HJ, Harrigan MR, Lau T, et al. Advancements in carotid
stenting leading to reductions in perioperative morbidity among
patients 80 years and older. Neurosurgery 2006;58:233–40.
9. Roubin GS, New G, Iyer SS, et al. Immediate and late clinical
outcomes of carotid artery stenting in patients with symptomatic and
asymptomatic carotid artery stenosis: a 5-year prospective analysis.
Circulation 2001;103:532–7.
0. McCrory DC, Goldstein LB, Samsa GP, et al. Predicting complica-
tions of carotid endarterectomy. Stroke 1993;24:1285–91.
1. Zahn R, Ischinger T, Hochadel M, et al., for the Arbeitsgemeinschaft
Leitende Kardiologische Krankenhausa¨rzte (ALKK). Carotid artery
stenting in octogenarians: results from the ALKK Carotid Artery
Stent (CAS) registry. Eur Heart J 2007;28:370–5. v2. Yen MH, Lee DS, Kapadia S, et al. Symptomatic patients have similar
outcomes compared with asymptomatic patients after carotid artery
stenting with emboli protection. Am J Cardiol 2005;95:297–300.
3. Marine LA, Rubin BG, Reddy R, Sanchez LA, Parodi JC, Sicard GA.
Treatment of asymptomatic carotid artery disease: similar early out-
comes after carotid stenting for high-risk patients and endarterectomy
for standard-risk patients. J Vasc Surg 2006;43:953–8.
4. Narins CR, Illig KA. Patient selection for carotid stenting versus
endarterectomy: a systematic review. J Vasc Surg 2006;44:661–72.
5. Bates ER, Babb JD, Casey DE, et al. ACCF/SCAI/SVMB/SIR/
ASITN 2007 clinical expert consensus document on carotid stenting:
a report of the American College of Cardiology Foundation Task
Force on Clinical Expert Consensus Documents (ACCF/SCAI/
SVMB/SIR/ASITN Clinical Expert Consensus Document Commit-
tee on Carotid Stenting). J Am Coll Cardiol 2007;49:126–70.
APPENDIX
or a list of core laboratories (Online Appendix 1), references used in the
PC calculation (Online Appendix 2), and investigators and institutions
articipating in the BEACH trial (Online Appendix 3), please see the online
ersion of this article.
